Comparative Pharmacology
Head-to-head clinical analysis: HIWOLFIA versus RAUVAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HIWOLFIA versus RAUVAL.
HIWOLFIA vs RAUVAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective agonist at central nervous system GABA-A receptors, enhancing inhibitory neurotransmission.
Rauval (rauwolfia serpentina alkaloids) depletes catecholamines and serotonin from peripheral sympathetic nerve endings and the brain by binding to and inhibiting vesicular monoamine transporters (VMAT), thus reducing sympathetic outflow. This leads to vasodilation, decreased peripheral vascular resistance, and reduced blood pressure.
Not established; investigational agent.
1.5 mg orally once daily, increased to 3 mg per day if needed. Maximum dose 6 mg per day.
None Documented
None Documented
Terminal elimination half-life is 18 hours (range 14-22 hours). Clinically, this supports once-daily dosing in most patients; however, in renal impairment (CrCl <30 mL/min), half-life extends to 40 hours, requiring dose adjustment.
Terminal elimination half-life is 7-10 hours in normal renal function; prolonged to 14-20 hours in renal impairment, requiring dose adjustment.
Renal excretion accounts for 70% of elimination, with 30% via biliary/fecal routes. Of the renal component, 90% is eliminated unchanged, 10% as metabolites.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Category C
Category C
Antihypertensive
Antihypertensive